Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus. / Vilsbøll, Tina; Knop, Filip Krag.

In: Ugeskrift for Laeger, Vol. 169, No. 22, 28.05.2007, p. 2101-5.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Vilsbøll, T & Knop, FK 2007, 'Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus', Ugeskrift for Laeger, vol. 169, no. 22, pp. 2101-5.

APA

Vilsbøll, T., & Knop, F. K. (2007). Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus. Ugeskrift for Laeger, 169(22), 2101-5.

Vancouver

Vilsbøll T, Knop FK. Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus. Ugeskrift for Laeger. 2007 May 28;169(22):2101-5.

Author

Vilsbøll, Tina ; Knop, Filip Krag. / Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus. In: Ugeskrift for Laeger. 2007 ; Vol. 169, No. 22. pp. 2101-5.

Bibtex

@article{2e7d4d7de72f4cdaab05ab604ab1e5af,
title = "Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus",
abstract = "Oral administration of glucose stimulates insulin secretion to a greater extent than does glucose administered as an isoglycaemic intravenous glucose infusion. This phenomenon is called the incretin effect and is caused by the two incretin hormones GIP and GLP-1. In patients with type 2 diabetes, the incretin effect is impaired. The mechanisms of the impaired incretin effect have been found to involve reduced secretion of GLP-1 and a severely impaired effect of GIP. It is currently unknown whether these defects are consequences of the diabetic state or primary pathogenetic factors.",
author = "Tina Vilsb{\o}ll and Knop, {Filip Krag}",
year = "2007",
month = may,
day = "28",
language = "Dansk",
volume = "169",
pages = "2101--5",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "22",

}

RIS

TY - JOUR

T1 - Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus

AU - Vilsbøll, Tina

AU - Knop, Filip Krag

PY - 2007/5/28

Y1 - 2007/5/28

N2 - Oral administration of glucose stimulates insulin secretion to a greater extent than does glucose administered as an isoglycaemic intravenous glucose infusion. This phenomenon is called the incretin effect and is caused by the two incretin hormones GIP and GLP-1. In patients with type 2 diabetes, the incretin effect is impaired. The mechanisms of the impaired incretin effect have been found to involve reduced secretion of GLP-1 and a severely impaired effect of GIP. It is currently unknown whether these defects are consequences of the diabetic state or primary pathogenetic factors.

AB - Oral administration of glucose stimulates insulin secretion to a greater extent than does glucose administered as an isoglycaemic intravenous glucose infusion. This phenomenon is called the incretin effect and is caused by the two incretin hormones GIP and GLP-1. In patients with type 2 diabetes, the incretin effect is impaired. The mechanisms of the impaired incretin effect have been found to involve reduced secretion of GLP-1 and a severely impaired effect of GIP. It is currently unknown whether these defects are consequences of the diabetic state or primary pathogenetic factors.

M3 - Tidsskriftartikel

VL - 169

SP - 2101

EP - 2105

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 22

ER -

ID: 34145135